A Case of Ketoacidosis Caused by Tirzepatide in Non-diabetic Individual

Read full text Summarise with VIRAT
Authors: Esraa Ahmed Bukhari, Samia Bokhari, Muneera Abd Ulmalik Alshareef, Turki Alharthi, Sally A. Aqabawi, Lama Arfaj, Nouf Abdulkarim Al Shehri, Abdulrahman Hashem Shilli, Dheyya Faiez Alnajar
Cited by: 0
References: 14

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Background: A new agonist for the glucagon-like peptide 1/glucose-dependent insulinotropic peptide (GLP-1/GIP) receptor is trizepatide. It was just approved to help non-diabetic persons lose weight and treat their diabetes. Case description: Due to the potential for starving ketoacidosis and insulin resistance, we report case of ketoacidosis following administration of trizepatide in an obese non-diabetic patient. Conclusion: Trizepatide, a dual-acting GLP-1 and GIP receptor agonist, can cause ketoacidosis in patients who are obese but not diabetic.

Fields of Study & Subjects

Diabetes Treatment and Management Pharmacology and Obesity Treatment Diet and metabolism studies

Publication details

Journal / source
International Journal of Innovative Research in Medical Science
Volume
11
Issue
03
Pages
102–104
Publication date
1 January 2026
Language
EN